Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 14Plasma cell 11Lymphoid 11Sarcoma 4Gynecologic 4Myeloid 3Gastrointestinal 3Dermatologic 3CNS 2Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Breast 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × selinexor × Endocrine × Clear all
NCT02250885 2019-09-17

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Gabrail Cancer Center Research

Phase 2 Completed
14 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡